OA10976A - Pharmaceutical compositions of corticotropin releasing hormone antagonists - Google Patents

Pharmaceutical compositions of corticotropin releasing hormone antagonists Download PDF

Info

Publication number
OA10976A
OA10976A OA9900034A OA9900034A OA10976A OA 10976 A OA10976 A OA 10976A OA 9900034 A OA9900034 A OA 9900034A OA 9900034 A OA9900034 A OA 9900034A OA 10976 A OA10976 A OA 10976A
Authority
OA
OAPI
Prior art keywords
dimethyl
phenoxy
ethyl
trimethyl
propoxy
Prior art date
Application number
OA9900034A
Other languages
English (en)
Inventor
Chen Yuhpyng Liang
Fossa Anthony Andrea
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA10976A publication Critical patent/OA10976A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (30)

19 a ...... V. i il*Zi Îad&'jwJ) 310976 10 15 20 25
1. Use of 4-{l-ethyl-propoxy)-3,6-dimethyl-2-(2.4,6-tnmeTnyl-pnenoxy)-pynaîneor (3,6<J!Œetfiyl-2’(2AS<rin39inyl^h?noxy^pyrid:n>4-ylH'l-etnyl-propyl)-arri!ne, a prodrugthereof nr a pharmaceutlcaliy acceptable sait thereof or cf said prodrug «n tne manufactureof a médicament for treating heart faillira in a msmmal.
2. A use of claim 1 wherein 4-(l-etnyl-propûxy)-3,6-dimethyl-2-(2.4,6-tnmethyl-phenoxyj-pyndine or a pharmaceuticaiiy acceptable sait thereof is administered.
3. A use of daim 2 whsrein 4-(1-ethyl-propoxy>«3.6’dimethyi-2-(2,4.6-trimethyl-phencxybpyrfdlne is adminstered.
4. A use of claim 2 wh.erein the mammal is a human. 5 A use of claim 2 whsrem tns mammal Is a compariicn animal.
5. A use cf daim 2 wherein me nean faüure is congestive heart failure.
7. A use of claim 6 wherein 4-(t-e!nyl-propoxy)-3,6*dlm2thyl-2-(2,4,e-tnmeîhyÎ- pnenoxyj-pyridme js adminstered. Ô. A use of daim o wherein the mammal i3 a human. U. A use of claim 8 wherein the congestive heart failure does not worsen.
10. A usg of ciairn G wnerein tne rnammai is a companion animal.
11. A use cf daim 1 wherein (3,C>dimetnyl-2’(2,4.6-trlinethyl-pnenoxy)'pyriOin-4>ytj-(1-emyi-propyi)»amine or a pharmaceuticaily acceptable sait thereof is administered.
12. A use of claim Π wherein (3,S’û’imethyl-2-(2,4,6-trimemyl-phenûxy)-pyridiÎ>4-y 1)-(1-othyl-prcpy!)-amine is administered.
13. A use of claim 11 wnerein the mammal is a human.
14. A use of daim 11 wherein the mammal is a companion animal.
15. A use of daim 11 wherein the heart failure is congestive heart failure.
16. A use of daim 15 wnerein (3,6-dimethyl-2-(2,4,6'trimewyl-phenûxy?pyridJn·4-yl.K1-ethyI-propyl)-amine is administered.
17. A use of daim 15 wherein the mammal is a human.
18. Λ use of ciairn 17 wherein the congestive heart failure does not worsen.
19. Λ use of claim 15 wherein the mammal is a companion animal.
20. A pharmaccutical composition comprising (a) 4-{1 -etnyl-prcpcxy}-3.5-dim3myt-2-(2A8’thmGthyl~pnenûXy)-pyriaine or (3,<3*dimcîhyl-2-(2,4.6‘trimaihyl-phenoxy)- pyndin-T’yiHl-ethyi-propcxy)-am:n9, a prodrug tr *rcof or a pharmsccuiically acceptable sait thereof or of sa-.d prodrug, (h) a cangss'iva heart tailuro treeting agent and iC) apharmcoeutically acceptable carrier or diluent. 30 ι>·ι> i ju ι. umju; J «,. 4 x A
w 010976
21. A pnarmacauticai composition cf daim 20 wherein said congestive heartfaiiure treating agent is a cardiac glycoside, a toop diuretic, a thiazide diuretic, a potassiumion sparing diuretic, an angiotensin convertlng enzyme ïnnifcntor, en angtotansion receptorantagonist, a nitrovasodiiaior, a pnosphodiesterase înnipitor. a direct vasodilator, an o,-adrenergic receptor antagonisb a calcium channel blocker or a sympathomimetic agent
22. A pharmaceutical composition of daim 21 comprising 4-(1-ethyl-pnopoxy>-3,Q-dÎmeihyl-2-(2,4.6-trimethyl-phenoxy)«pyridÎne. 23. a pharmoceutical composition of daim 22 comprising 4-(1-ethyl-propoxy}- S.S-dimstnyi^-fSAB-trimethyl-phenoxyJ-pyridine.
24. Λ pharmaceutical composition of daim 23 wherein said calcium channelPlocxor Is amlcdipine. 15 20 25 30 35 25. a pharmaceutical composition of daim 21 comprising (3.6-dimethyf-2-(2,4,6-trÎmethyi-pnenaxy}’pyridin-4'yi)-{l-ethyi-propoxy)-aminG or a pharmaceutically acceptablesait thereof.
20. A pharmaceutical composition of daim 25 comprising (3,G-dimethyl-2-{2.4.6-trimetfiyl-plienoxy}-pyridin-4-y()’( 1 -ethyi-prapoxy)-amlne.
27. A pharmaceutical composition of daim 26 wherein said calcium channelblocker is emiodipina. 28. usa of a pnarmnccutical composition of claim 20 in the manufacture of ameaicament for treanng neart faiiure în a mammai.
29. A usa of daim 28 wherein said congestive heart faiiure treating agent îa acardiac glycoside. a loop diuretic. a thiazide diuretic, a potassium ion spanng diuretic. ansngiotensin convertmg enzyme inhibitor, an angiotension receptor antagonist, ar.iîrovascdilator, a phosphodiesterase inhibitor, a direct vasodilator, an α,-adrenergjcreceptor antagonist, a calcium channel docker or a sympathomimetic agent.
30. Λ use cf daim 29 comprif’ng 4<1-eihyl^repoxy)<3,8<imethyl-2-(2,4,i>·trimethyl-pnenoxyj-pyn’dine or a pharmncouticslly acceptable sait thereof.
31. A use of daim 30 wnsrein the mesylata sait of 4-{1-ethy!-propcxy)-3,6-cimethyl-2«(2,4,6-trimethy,'--:.',snoxy)'py.'.’ t:nc is adminriered. 32 λ usa cf ciîiim 31 wherein said calcium ^harintii blocker is amlc-.pmo.
33. A use of claim 29 comprising (3,S<timethyl-2-{2,4.G4r;methyl^henoxy)-pyriûin- T-yO-(i-ethy|-prcpoxy)-amine or a pharmaceuticaily acceptable sait thereof.
34. A usa of claim 33 wherein (3,6-dimeinyl-2-(2,4,8-trirnetny!-phenoxy}-pyn‘d:h·a-yi?-(1'-athyl-prcpoxy)-am!ne is aûministered. 05. a usa of claim 34 v srem said calcium channel blocker is amlodipina. 21 010976
38. A kit compneing a. an amount of a compound, said compound bemg seleoed front 4-{1-ethyl‘propoxy)-3,6-dimethyl-2-(2,4.8-trimetnyl-pnenoxy>pyrtdine, (3,6ΌίτηΒΐηγΙ-2-{2Α6-trimethyl-pnenoxyJ-pyridin-4-yij-(i-etnyl-propoxyj-amine, a prodrug theraof, and a 5 pnarmaceuticajiy acceptante sait of said compound or said tait în a finît unit dosage form; b- an amount Qf a congestive heart failura treating agent; and c, a container. 37 A kit of daim 36 wnerein said congestive neart failure treating agent is acaraiac glycosïde, a loop diuretic. a thiaziûe diuretic, a potassium ion spanng diuretic, an 10 «ngloiensm convertîng enzyme înhibitor, an angioterttion receptor antagonlst, a nltrovasodiiator, a phasphodiesterase înhibitor, a direct vasodiiator, an a,-adrenerg»crecaptor antagomst, a calcium channel biocker or a sympathomimetic agent
38. A kit of claim 37 compflsinq 4-(1-eW-pr0p0XY}-3,8-dimethyl-2-{2,4,6-trimethyl-phenoxyj-pyridlne or a pharmaceuticaiiy acceptable sait tnereof. 15 39. A kit of claim 38 wherem 4-(i-etnyi-pfôpaxy)-3,e-dimeinyi-2-(2,4.6-tnmetnyl- phenoxyhpyndine ia administared.
40. A kit of cjaim 39 wherein said calcium channel Olocker is amlodipin·.
41. A kit of daim 40 comprising (3(6'dimetbyl-2-(2A0-tnmewyhpnenoxy)-pyrtdin-4-y l}-{1 -eihyi-propûxy)-arnine. 20 42. A kit of claim 41 wherem O.e-dimettiyl^-iS^.â-trimethyl-phenoxyhpyriain-l- yi)-(i-etnyl-propoxy)-amine is adrïtfnistered.-
43. A kit of daim 42 wherem said calcium channel docker is amlodipine.
OA9900034A 1998-02-17 1999-02-16 Pharmaceutical compositions of corticotropin releasing hormone antagonists OA10976A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7493498P 1998-02-17 1998-02-17

Publications (1)

Publication Number Publication Date
OA10976A true OA10976A (en) 2001-11-05

Family

ID=22122537

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900034A OA10976A (en) 1998-02-17 1999-02-16 Pharmaceutical compositions of corticotropin releasing hormone antagonists

Country Status (28)

Country Link
US (1) US6043260A (fr)
EP (1) EP0951906A1 (fr)
JP (1) JPH11292766A (fr)
KR (1) KR19990072616A (fr)
CN (1) CN1231176A (fr)
AP (1) AP9901464A0 (fr)
AR (1) AR017723A1 (fr)
AU (1) AU1732999A (fr)
BG (1) BG103180A (fr)
BR (1) BR9900653A (fr)
CA (1) CA2262252C (fr)
EA (1) EA199900124A3 (fr)
GT (1) GT199900015A (fr)
HR (1) HRP990054A2 (fr)
HU (1) HUP9900386A3 (fr)
ID (1) ID23218A (fr)
IL (1) IL128531A0 (fr)
IS (1) IS4975A (fr)
MA (1) MA26608A1 (fr)
NO (1) NO990722L (fr)
OA (1) OA10976A (fr)
PA (1) PA8467401A1 (fr)
PE (1) PE20000266A1 (fr)
PL (1) PL331507A1 (fr)
SG (1) SG81261A1 (fr)
TN (1) TNSN99024A1 (fr)
TR (1) TR199900328A2 (fr)
ZA (1) ZA991220B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
EP1216037A2 (fr) 1999-09-21 2002-06-26 Emory University Procedes et compositions pour le traitement de troubles lies aux plaquettes au moyen d'agents inhibiteurs de trajet de mpl
BR0107662A (pt) * 2000-01-18 2002-11-19 Pfizer Prod Inc Antagonistas do fator de liberação de corticotropina
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US7015229B2 (en) 2002-02-22 2006-03-21 Pfizer Inc Substituted pyrimidinones and pyrimidinthiones
CA2478715A1 (fr) * 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Nouveaux derives de pyrazolo(1,5-a)pyridine utilises en tant que modulateurs du neurotransmetteur
JP2005533014A (ja) * 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
MXPA05002418A (es) * 2002-09-12 2005-05-27 Pharmacia & Upjohn Co Llc Derivados de 1,4-pirazina sustituidos.
AR041470A1 (es) * 2002-10-17 2005-05-18 Upjohn Co Compuestos de pirrolo (1,2 - b) piridazina y sus usos
MXPA05005408A (es) * 2002-11-21 2005-08-03 Pharmacia & Upjohn Co Llc Compuestos de pirazina como moduladores de factor de liberacion de corticotropina.
WO2004094408A1 (fr) * 2003-04-23 2004-11-04 Pharmacia & Upjohn Company Llc Pyrimidinones et pyrimidinthiones substituees en tant qu'antagonistes de la corticoliberine
CA2523072A1 (fr) * 2003-05-07 2004-11-18 Pharmacia & Upjohn Company Llc Composes pyrrolo[1,2-b]pyridaziniques
JP2006525989A (ja) * 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Cns障害を治療するためのcrf1受容体アンタゴニストとしてのピラジノン
CA2524352A1 (fr) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Derives pyrimidiques substitues
CA2524519A1 (fr) * 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Composes utilises comme antagonistes du recepteur de type 1 de la corticoliberine (crf)
US20050209289A1 (en) * 2004-03-16 2005-09-22 Talarico Matthew T Method for vascular dysregulation
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique

Also Published As

Publication number Publication date
AR017723A1 (es) 2001-09-12
CA2262252C (fr) 2006-01-10
TNSN99024A1 (fr) 2005-11-10
HUP9900386A2 (hu) 1999-11-29
EP0951906A1 (fr) 1999-10-27
US6043260A (en) 2000-03-28
PL331507A1 (en) 1999-08-30
PE20000266A1 (es) 2000-04-07
JPH11292766A (ja) 1999-10-26
BG103180A (bg) 1999-09-30
EA199900124A3 (ru) 1999-12-29
CN1231176A (zh) 1999-10-13
HU9900386D0 (en) 1999-04-28
SG81261A1 (en) 2001-06-19
GT199900015A (es) 2000-07-26
EA199900124A2 (ru) 1999-08-26
BR9900653A (pt) 2000-10-17
MA26608A1 (fr) 2004-12-20
NO990722D0 (no) 1999-02-16
ZA991220B (en) 2000-08-16
IS4975A (is) 1999-08-18
PA8467401A1 (es) 2000-09-29
IL128531A0 (en) 2000-01-31
HUP9900386A3 (en) 1999-12-28
HRP990054A2 (en) 2000-02-29
TR199900328A2 (xx) 1999-10-21
ID23218A (id) 2000-03-30
NO990722L (no) 1999-08-18
KR19990072616A (ko) 1999-09-27
AU1732999A (en) 1999-09-02
AP9901464A0 (en) 1999-03-31
CA2262252A1 (fr) 1999-08-17

Similar Documents

Publication Publication Date Title
OA10976A (en) Pharmaceutical compositions of corticotropin releasing hormone antagonists
EP0233461B2 (fr) 2-Pyrimidinamines substituées en 4,5 et 6
EP1399423B1 (fr) Amides d&#39;acide anthranilique comportant une chaine laterale heteroarylsulfonyle, procede de fabrication, utilisation en tant qu&#39;agent pharmaceutique ou diagnostique, et preparations pharmaceutiques contenant ces amides
JPS62281858A (ja) ピペリジン誘導体及びその類縁誘導体
TWI458719B (zh) 非核苷反轉錄酶抑制劑
WO2006042638A1 (fr) Derives de 5-arylamino-1h-pyridine-2-on substitues sur 3,6 et composes similaires utilises en tant qu&#39;inhibiteurs de la polymerase poly (adp-ribose) destines au traitement de maladies ou de lesions tissulaires provoques par une necrose ou une apoptose
EP1242069B1 (fr) Composes liant l&#39;albumine qui empechent la glycation non enzymatique et qui peuvent etre utilises dans le traitement de pathologies liees a la glycation
DE60313350T2 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
US20120309786A1 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
JP2003531856A (ja) リン酸輸送阻害剤
JP2010522168A (ja) 鉱質コルチコイドレセプターモジュレータ
TW445251B (en) Substituted indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them
JP2005515169A (ja) レトロウイルス感染の治療方法
DE60221152T2 (de) Diaryl-1,2,4-triazolderivate als hochselektive cyclooxygenase-2-inhibitoren
CZ51399A3 (cs) Farmaceutická kompozice a kit
JP2002155060A (ja) イミダゾール化合物及びその用途
KR101128372B1 (ko) 1h-피리딘-2-온 유도체
JPH0770083A (ja) イミダゾール誘導体を有効成分とする血圧降下剤
JPS6261978A (ja) 5−フルオロ−1h−ベンズイミダゾ−ル誘導体
JPS635082A (ja) ベンズイミダゾ−ル、その製法および胃酸分泌抑制剤としての処方物
KR20060098907A (ko) 피롤로[2,3-d]피리다진 유도체 및 그의 제조방법